Down-regulation of methylthioadenosine phosphorylase (MTAP) induces progression of hepatocellular carcinoma via accumulation of 5′-deoxy- 5′-methylthioadenosine (MTA)

American Journal of Pathology

Volumn 178, Issue 3, 2011, Pages 1145-1152

  Kirovski, Georgi ^a   Stevens, Axel P ^b   Czech, Barbara ^a   Dettmer, Katja ^b   Weiss, Thomas S ^a   Wild, Peter ^c   Hartmann, Arndt ^d   Bosserhoff, Anja K ^b   Oefner, Peter J ^b   Hellerbrand, Claus ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5' METHYLTHIOADENOSINE; 5' METHYLTHIOADENOSINE PHOSPHORYLASE; FIBROBLAST GROWTH FACTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MYOFIBROBLAST; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE;

EID: 79952758349     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2010.11.059     Document Type: Article

References (50)

1. Shariff MIF, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD: Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol 2009, 3:353-367
2. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD: Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008, 14:4300-4308
3. Hussain K, El-Serag HB: Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma. Minerva Gastroenterol Dietol 2009, 55:123-138
4. Mendizabal M, Reddy KR: Current management of hepatocellular carcinoma. Med Clin North Am 2009, 93:885-900, viii
5. Yu MC, Yuan JM: Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004, 127:S72-S78 (Pubitemid 39423372)
6. Lee JS, Thorgeirsson SS: Genetic profiling of human hepatocellular carcinoma. Semin Liver Dis 2005, 25:125-132
7. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM: Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007, 27:55-76
8. Lee JS, Thorgeirsson SS: Comparative and integrative functional genomics of HCC. Oncogene 2006, 25:3801-3809
9. Hellerbrand C, Mühlbauer M, Wallner S, Schuierer M, Behrmann I, Bataille F, Weiss T, Schölmerich J, Bosserhoff AK: Promoter- hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma. Carcinogenesis 2006, 27:64-72 (Pubitemid 43025245)
10. Backlund PS, Smith RA: Methionine synthesis from 5′- methylthioadenosine in rat liver. J Biol Chem 1981, 256:1533-1535
11. Pascale RM, Simile MM, De Miglio MR, Feo F: Chemoprevention of hepatocarcinogenesis: S-adenosyl-L-methionine. Alcohol 2002, 27: 193-198 (Pubitemid 34876922)
12. Olopade OI, Pomykala HM, Hagos F, Sveen LW, Espinosa R, Dreyling MH, Gursky S, Stadler WM, Le Beau MM, Bohlander SK: Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21. Proc Natl Acad Sci U S A: 1995, 92: 6489-6493
13. Christopher SA, Diegelman P, Porter CW, Kruger WD: Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ ARF), acts as a tumor suppressor in a breast cancer cell line. Cancer Res 2002, 62:6639-6644 (Pubitemid 35364132)
14. García-Castellano JM, Villanueva A, Healey JH, Sowers R, Cordon- Cardo C, Huvos A, Bertino JR, Meyers P, Gorlick R: Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. Clin Cancer Res 2002, 8:782-787 (Pubitemid 34742108)
15. Hori Y, Hori H, Yamada Y, Carrera CJ, Tomonaga M, Kamihira S, Carson DA, Nobori T: The methylthioadenosine phosphorylase gene is frequently co-deleted with the p16INK4a gene in acute type adult T-cell leukemia. Int J Cancer 1998, 75:51-56 (Pubitemid 28113977)
16. Wong YF, Chung TK, Cheung TH, Nobori T, Chang AM: MTAP gene deletion in endometrial cancer. Gynecol Obstet Invest 1998, 45:272-276 (Pubitemid 28241185)
17. Berasain C, Hevia H, Fernández-Irigoyen J, Larrea E, Caballería J, Mato JM, Prieto J, Corrales FJ, García-Trevijano E, Avila MA: Methylthioadenosine phosphorylase gene expression is impaired in human liver cirrhosis and hepatocarcinoma. Biochim Biophys Acta 2004, 1690:276-284 (Pubitemid 39423623)
18. Bonilla F, Orlow I, Cordon-Cardo C: Mutational study of p16CDKN2/ MTS1/INK4A and p57KIP2 genes in hepatocellular carcinoma. Int J Oncol 1998, 12:583-588
19. Liew CT, Li HM, Lo KW, Leow CK, Lau WY, Hin LY, Lim BK, Lai PB, Chan JY, Wang XQ, Wu S, Lee JC: Frequent allelic loss on chromosome 9 in hepatocellular carcinoma. Int J Cancer 1999, 81:319-324 (Pubitemid 29165186)
20. Herath NI, Kew MC, Walsh MD, Young J, Powell LW, Leggett BA, MacDonald GA: Reciprocal relationship between methylation status and loss of heterozygosity at the p14(ARF) locus in Australian and South African hepatocellular carcinomas. J Gastroenterol Hepatol 2002, 17:301-307 (Pubitemid 34534103)
21. Hellerbrand C, Amann T, Schlegel J, Wild P, Bataille F, Spruss T, Hartmann A, Bosserhoff AK: The novel gene MIA2 acts as a tumour suppressor in hepatocellular carcinoma. Gut 2008, 57:243-251 (Pubitemid 351158054)
22. Muhlbauer M, Bosserhoff AK, Hartmann A, Thasler WE, Weiss TS, Herfarth H, Lock G, Scholmerich J, Hellerbrand C: A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003, 125:1085-1093 (Pubitemid 37193455)
23. Weiss TS, Jahn B, Cetto M, Jauch KW, Thasler WE: Collagen sandwich culture affects intracellular polyamine levels of human hepatocytes. Cell Prolif 2002, 35:257-267
24. Mühlbauer M, Fleck M, Schütz C, Weiss T, Froh M, Blank C, Schölmerich J, Hellerbrand C: PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol 2006, 45:520-528 (Pubitemid 44307379)
25. Amann T, Maegdefrau U, Hartmann A, Agaimy A, Marienhagen J, Weiss TS, Stoeltzing O, Warnecke C, Schölmerich J, Oefner PJ, Kreutz M, Bosserhoff AK, Hellerbrand C: GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol 2009, 174:1544-1552
26. Stevens AP, Dettmer K, Kirovski G, Samejima K, Hellerbrand C, Bosserhoff AK, Oefner PJ: Quantification of intermediates of the methionine and polyamine metabolism by liquid chromatography-tandem mass spectrometry in cultured tumor cells and liver biopsies. J Chromatogr A 2010, 1217:3282-3288
27. Stevens AP, Dettmer K, Wallner S, Bosserhoff AK, Oefner PJ: Quantitative analysis of 5′-deoxy-5′-methylthioadenosine in melanoma cells by liquid chromatography-stable isotope ratio tandem mass spectrometry. J Chromatogr B:2008, 876:123-128
28. Muhlbauer M, Allard B, Bosserhoff AK, Kiessling S, Herfarth H, Rogler G, Scholmerich J, Jobin C, Hellerbrand C: Differential effects of deoxycholic acid and taurodeoxycholic acid on NF-kappa B signal transduction and IL-8 gene expression in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 2004, 286:G1000-G1008 (Pubitemid 38715663)
29. Amann T, Bataille F, Spruss T, Mühlbauer M, Gäbele E, Schölmerich J, Kiefer P, Bosserhoff AK, Hellerbrand C: Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci 2009, 100:646-653
30. Amann T, Hellerbrand C: GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets 2009, 13:1411-1427
31. Harada T, Arii S, Mise M, Imamura T, Higashitsuji H, Furutani M, Niwano M, Ishigami S, Fukumoto M, Seiki M, Sato H, Imamura M: Membrane-type matrix metalloproteinase-1(MT1-MTP) gene is overexpressed in highly invasive hepatocellular carcinomas. J Hepatol 1998, 28:231-239 (Pubitemid 28116431)
32. Kubo F, Ueno S, Hiwatashi K, Sakoda M, Kawaida K, Nuruki K, Aikou T: Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Ann Surg Oncol 2005, 12:800-807 (Pubitemid 41355932)
33. Mise M, Arii S, Higashituji H, Furutani M, Niwano M, Harada T, Ishigami S, Toda Y, Nakayama H, Fukumoto M, Fujita J, Imamura M: Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 1996, 23:455-464 (Pubitemid 26087158)
34. Yang P, Yuan W, He J, Wang J, Yu L, Jin X, Hu Y, Liao M, Chen Z, Zhang Y: Overexpression of EphA2. MMP-9, and MVD-CD34 in hepatocellular carcinoma: implications for tumor progression and prognosis Hepatol Res 2009, 39:1169-1177
35. Desmoiliére A, Guyot C, Gabbiani G: The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 2004, 48:509-517 (Pubitemid 39360401)
36. Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer 2006, 6:392-401
37. Garcia-Roman R, Salazar-Gonzalez D, Rosas S, Arellanes-Robledo J, Beltran-Ramirez O, Fattel-Fazenda S, Villa-Trevino S: The differential NF-kB modulation by S-adenosyl-L-methionine. N-acetylcysteine and quercetin on the promotion stage of chemical hepatocarcinogenesis Free Radic Res 2008, 42:331-343
38. Arsura M, Cavin LG: Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett 2005, 229:157-169
39. Luedde T, Trautwein C: Intracellular survival pathways in the liver. Liver Int 2006, 26:1163-1174 (Pubitemid 44741203)
40. Qiao L, Zhang H, Yu J, Francisco R, Dent P, Ebert MP, Rocken C, Farrell G: Constitutive activation of NF-kappaB in human hepatocellular carcinoma: evidence of a cytoprotective role. Hum Gene Ther 2006, 17:280-290
41. Cerri MA, Beltrán-Nuñez A, Bernasconi S, Dejana E, Bassi L, Bazzoni G: Inhibition of cytokine production and endothelial expression of adhesion antigens by 5′-methylthioadenosine. Eur J Pharmacol 1993, 232:291-294 (Pubitemid 23080208)
42. Di Padova F, Di Padova C, Stramentinoli G, Tritapepe R: Inhibition of lymphocyte function by a naturally occurring nucleoside: 5′- methylthioadenosine (MTA). Int J Immunopharmacol 1985, 7:193-198 (Pubitemid 15075820)
43. Hevia H, Varela-Rey M, Corrales FJ, Berasain C, Martinez-Chantar ML, Latasa MU, Lu SC, Mato JM, Garcia-Trevijano ER, Avila MA: 5′- methylthioadenosine modulates the inflammatory response to endotoxin in mice and in rat hepatocytes. Hepatology 2004, 39:1088-1098 (Pubitemid 38428948)
44. Ansorena E, García-Trevijano E, Martínez-Chantar ML, Huang ZZ, Chen L, Mato JM, Iraburu M, Lu SC, Avila MA: S-adenosylmethionine and methylthioadenosine are antiapoptotic in cultured rat hepatocytes but proapoptotic in human hepatoma cells. Hepatology 2002, 35:274-280 (Pubitemid 34106365)
45. Avila MA, García-Trevijano E, Lu S, Corrales F, Mato J: Methylthioadenosine. Int J Biochem Cell Biol 2004, 36:2125-2130 (Pubitemid 39094435)
46. de Ferra F, Baglioni C: Correlation between growth inhibition and presence of 5′-methylthioadenosine in cells treated with interferon. Cancer Res 1984, 44:2297-2301
47. Maher PA: Inhibition of the tyrosine kinase activity of the fibroblast growth factor receptor by the methyltransferase inhibitor 5′- methylthioadenosine. J Biol Chem 1993, 268:4244-4249
48. Riscoe MK, Schwamborn J, Ferro AJ, Olson KD, Fitchen JH: Inhibition of growth but not differentiation of normal and leukemic myeloid cells by methylthioadenosine. Cancer Res 1987, 47:3830-3834 (Pubitemid 17105734)
49. Shafman TD, Sherman ML, Kufe DW: Effect of 5′-methylthioadenosine on induction of murine erythroleukemia cell differentiation. Biochem Biophys Res Commun 1984, 124:172-177 (Pubitemid 15207675)
50. Basu I, Cordovano G, Das I, Belbin TJ, Guha C, Schramm VL: A transition state analogue of 5′-methylthioadenosine phosphorylase induces apoptosis in head and neck cancers. J Biol Chem 2007, 282:21477-21486 (Pubitemid 47099931)